Petiq Intrinsic Value – PETIQ Reports 24.8% Revenue Increase and 104.5% Net Income Increase in Q2 2023

August 12, 2023

☀️Earnings Overview

For the quarter ending June 30, 2023, PETIQ ($NASDAQ:PETQ) reported total revenue of USD 314.6 million and a net income of USD 9.5 million – an increase of 24.8% and 104.5% respectively, compared to the same period one year prior.

Analysis – Petiq Intrinsic Value

GoodWhale recently conducted an analysis of PETIQ‘s financials. Our proprietary Valuation Line calculated the fair value of PETIQ share to be around $24.2. However, the stock is currently traded at $17.4, resulting in a significant undervaluation of 28.1%. This implies that investors may benefit from purchasing the stock at its current price point. In addition, PETIQ’s financials indicate that it is well-positioned to perform strongly, given its solid balance sheet and promising market prospects. Thus, GoodWhale recommends investing in PETIQ’s stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Petiq. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…

    Total Revenues Net Income Net Margin
    998.82 -36.8 -0.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Petiq. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…

    Operations Investing Financing
    127.81 -35.71 -18.99
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Petiq. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…

    Total Assets Total Liabilities Book Value Per Share
    883.47 647.87 8.01
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Petiq are shown below. PETIQ_Reports_24.8_Revenue_Increase_and_104.5_Net_Income_Increase_in_Q2_2023″>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    7.9% 86.4% -0.3%
    FCF Margin ROE ROA
    12.0% -1.0% -0.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items




  • Peers

    The pet industry is a competitive one, with many companies vying for a share of the market. PetIQ Inc is one such company, and it competes with China Health Industries Holdings Inc, Healthy Extracts Inc, and BioGaia AB, among others.

    – China Health Industries Holdings Inc ($OTCPK:CHHE)

    The company’s market cap is 12.19M as of 2022, a Return on Equity of -0.5%. The company focuses on the development, manufacture and sale of health products in China.

    – Healthy Extracts Inc ($OTCPK:HYEX)

    Healthy Extracts Inc is a company that produces and sells health supplements. The company has a market cap of 17.93M as of 2022 and a Return on Equity of -25.8%. The company’s products are designed to improve the health and well-being of its customers.

    – BioGaia AB ($LTS:0GTN)

    BioGaia is a Swedish pharmaceutical company that focuses on developing and commercializing probiotics. The company’s products are based on lactic acid bacteria, which are found in the human body and are known to have numerous health benefits. Probiotics are live microorganisms that, when consumed in adequate amounts, can confer a health benefit on the host. BioGaia’s products are available in over 90 countries and are sold in a variety of formats, including capsules, tablets, liquids, and powders.

    BioGaia’s market cap is 8.71B as of 2022. The company has a Return on Equity of 12.29%. BioGaia’s products are based on lactic acid bacteria, which are found in the human body and are known to have numerous health benefits. Probiotics are live microorganisms that, when consumed in adequate amounts, can confer a health benefit on the host.

    Summary

    Investors should take note of PETIQ‘s strong financial performance in the quarter ending June 30, 2023. The company reported total revenue of USD 314.6 million, a 24.8% increase from the same period the previous year. Similarly, net income for the period was USD 9.5 million, a remarkable 104.5% increase year-on-year. Such impressive growth indicates a potentially lucrative opportunity for shareholders and could be an attractive option for those looking to diversify their portfolio.

    Recent Posts

    Leave a Comment